Tuberculosis (TB) along with acquired immune deficiency syndrome and malaria rank
among the top three fatal infectious diseases which pose threat to global public health …

In the last two decades, multi (MDR), extensively (XDR), extremely (XXDR) and total (TDR)
drug-resistant Mycobacterium tuberculosis (M. tb) strains have emerged as a threat to public …

Tuberculosis (TB) is an infectious disease that poses a serious threat to human health.
Rifampin (RIF) is an important first-line anti-TB drug, and rifampin resistance (RIF-R) is a key …

Antimicrobials (eg, antibiotics and biocides) are invaluable chemicals used to control
microbes in numerous contexts. Because of the simultaneous use of antibiotics and …

Whole-cell screening for Mycobacterium tuberculosis (Mtb) inhibitors is complicated by the
pathogen's slow growth and biocontainment requirements. Here we present a synthetic …

Antibiotic-resistant tuberculosis continues to be one of the major threats to global
tuberculosis control. After a hiatus of over 40 years in antituberculosis drug development, the …

The latest WHO report estimates about 1.6 million global deaths annually from TB, which is
further exacerbated by drug-resistant (DR) TB and comorbidities with diabetes and HIV …

Mycobacterium tuberculosis (Mtb) is the causative pathogen of tuberculosis, the most lethal
infectious disease resulting in 1.3 million deaths annually. Treatments against Mtb are …

As the first identified multidrug efflux pump in Mycobacterium tuberculosis (Mtb), EfpA is an
essential protein and promising drug target. However, the functional and inhibitory …

The highly adaptive cellular response of Mycobacterium tuberculosis to various antibiotics
and the high costs for clinical trials, hampers the development of novel antimicrobial agents …